Introduction
============

Endogenous Cushing's syndrome is an endocrine disease resulting from chronic exposure to excessive glucocorticoids produced in the adrenal cortex.[@b1-ndt-10-1763] Adrenocorticotropic hormone (ACTH)-secreting tumors, mainly of pituitary origin (Cushing's disease), are the most common form of endogenous Cushing's syndrome, and cortisol-secreting adrenal tumors are responsible for approximately 20% of cases of this syndrome in Western populations and for 40% in the Japanese population.[@b2-ndt-10-1763],[@b3-ndt-10-1763]

Although endogenous or exogenous Cushing's syndrome produces a variety of physical clinical features, such as truncal obesity, thin skin, easy bruising, proximal weakness, osteopenia, gonadal dysfunction, hypertension, and glucose intolerance, it also affects the central nervous system. Studies have shown that many patients with Cushing's syndrome present with cognitive or psychological alterations.[@b1-ndt-10-1763],[@b2-ndt-10-1763],[@b4-ndt-10-1763] Furthermore, several studies confirmed the occurrence of diffuse brain atrophy associated with cognitive impairment in both children and adults with all types of Cushing's syndrome.[@b5-ndt-10-1763]--[@b9-ndt-10-1763] Although the ultimate outcomes remain uncertain, these central nervous system alterations persist over several years even after resolution of hypercortisolemia[@b10-ndt-10-1763],[@b11-ndt-10-1763] and contribute to long-term impairment in quality of life.[@b12-ndt-10-1763] Here, we report a case of cognitive dysfunction with brain atrophy in an adolescent patient with Cushing's syndrome.

Case report
===========

A 19-year-old Japanese male visited a local general hospital in July 2011 after 5 days of behavioral abnormalities, such as money wasting or nighttime wandering. His family history was unremarkable. He had never consumed alcohol or smoked cigarettes. He had been healthy until the appearance of a rounded face 12 months prior to the visit, and 9 months later he was found to have hypertension upon routine medical checkup. He developed insomnia, a short temper, and restlessness 1 month before the visit. Magnetic resonance imaging (MRI) of the brain revealed no focal lesions but diffuse brain atrophy, including in the cerebrum, cerebellum, and hippocampus ([Figure 1, A--C](#f1-ndt-10-1763){ref-type="fig"}). Because the laboratory examination showed hypokalemia and high random plasma cortisol levels (28.7 μg/dL) at 10 AM, he was referred to our hospital for further endocrine function evaluation in August 2011.

His consciousness was clear, but he presented with disorientation, planotopokinesia, and impaired reality-testing, with a global assessment of functioning score of 38 out of 100 using the Reintegration to Normal Living Index.[@b13-ndt-10-1763] His height and weight were 168.8 cm and 56.3 kg, respectively. His blood pressure and pulse rate were 175/105 mmHg and 63 beats per minute, respectively, under antihypertensive treatment with olmesartan 20 mg/day. No chest rales or heart murmurs were detected. He exhibited a rounded face, thin skin, easy bruising, purple skin striae on the bilateral buttocks, and mild peripheral edema. Laboratory findings showed ACTH-independent hypercortisolemia and hypokalemia while under oral administration of 1,800 mg/day potassium chloride ([Table 1](#t1-ndt-10-1763){ref-type="table"}). A circadian rhythm in plasma cortisol levels was absent, and plasma ACTH was undetectable. An oral dose of dexamethasone (1 mg) at 11 PM did not suppress plasma cortisol levels (25.5 μg/dL) the following morning. Abdominal computed tomography demonstrated a left adrenal tumor, and ^131^I-adosterol scan revealed marked uptake on the same side ([Figure 2](#f2-ndt-10-1763){ref-type="fig"}), suggesting a diagnosis of primary adrenal Cushing's syndrome. His hypertension was treated with a combination of amlodipine (10 mg/day) and olmesartan (40 mg/day). Upon presentation to the psychiatric service, he was considered to have cognitive disturbance possibly due to Cushing's syndrome, and was followed up closely without therapy.

Laparoscopic left adrenalectomy was performed in September 2011. Microscopic examination was consistent with a benign cortisol-secreting adrenocortical adenoma ([Figure 3](#f3-ndt-10-1763){ref-type="fig"}). Following surgery, intravenous administration of hydrocortisone was initiated, and then oral hydrocortisone (20 mg/day) was maintained. His peak plasma levels of ACTH and cortisol after intravenous corticotropin-releasing hormone (1 mg) were 5.2 pg/mL (at 30 minutes) and 0.3 μg/dL (at 60 minutes), respectively, under maintenance replacement therapy 2 weeks after surgery.

His postoperative course was uncomplicated, and his blood pressure levels and serum potassium concentration normalized without the need for medication. Behavioral abnormalities were no longer observed after surgery, and he was finally classified as cured of his cognitive disturbance caused by Cushing's syndrome at the psychiatric service in February 2012. The Cushingoid features disappeared, and MRI of the brain performed 8 months after surgery revealed recovery of the brain volume ([Figure 1, D--F](#f1-ndt-10-1763){ref-type="fig"}). The dilatation of ventricles, subarachnoid space, and sulci were also resolved, and scores for estimating ventricular volume were reduced from 0.25 to 0.22 according to the Evans' index.[@b14-ndt-10-1763] Thirty months after surgery, his right adrenal function was found to have normalized, and the replacement therapy was discontinued. His mental status improved markedly, with a Reintegration to Normal Living Index of 92 out of 100. The patient is being followed up in the outpatient clinic, and his subsequent clinical course has been uneventful.

Discussion
==========

We described an adolescent Japanese patient with cognitive impairment and brain atrophy associated with Cushing's syndrome, whose brain volume and cognitive function recovered rapidly after treatment of hypercortisolemia by removing cortisol-secreting adrenal adenoma.

Brain atrophy can occur in a wide variety of conditions other than aging, and notable causes include exogenous or endogenous steroids, chronic alcohol ingestion, radiation therapy, or anorexia nervosa.[@b5-ndt-10-1763]--[@b7-ndt-10-1763],[@b15-ndt-10-1763] None of the conditions other than excessive endogenous steroid hormones was present in our patient. Therefore, it is plausible that diffuse brain atrophy was caused by endogenous Cushing's syndrome in our case.

The patient exhibited decreased brain volume in the cerebral and cerebellar hemispheres, including the hippocampus, along with dilatation of the ventricles, subarachnoid space, and sulci on MRI. These morphological brain changes were consistent with previously reported changes in patients with endogenous Cushing's syndrome.[@b9-ndt-10-1763],[@b15-ndt-10-1763]

The prognosis of central nervous system alterations caused by endogenous Cushing's syndrome has been suggested to differ between adults and children. Studies of successfully treated adults with Cushing's syndrome showed no change or only partial amelioration of cognitive impairment within 1 year[@b16-ndt-10-1763]--[@b19-ndt-10-1763] and partial reversal of brain atrophy with follow-up over several years.[@b20-ndt-10-1763]--[@b22-ndt-10-1763] In contrast, a study of eleven children under the age of 16 years with Cushing's syndrome with a mean duration of 4.4 years showed almost complete reversal of brain atrophy but a subsequent decline in cognitive function during the 1 year following correction of hypercortisolemia.[@b8-ndt-10-1763] In the present case, an adolescent patient with a 1-year duration of Cushing's syndrome experienced the reversal of cognitive dysfunction and brain atrophy within approximately 6 months following successful surgical treatment of hypercortisolemia. In addition, the patient presented no recurrent cognitive alterations during approximately 3 years post-surgery. These findings suggest that the young age at onset and the short duration of Cushing's syndrome probably contributed to the rapid reversibility of both cognitive dysfunction and brain atrophy in our case. Long-term follow-up is, however, required, especially with regard to cognitive function.

The pathogenesis of brain atrophy in Cushing's syndrome is thought to be multifactorial, and possible explanations include loss of water content in brain tissue, catabolic effects on proteins, reduction in glucose metabolism, synaptic accumulation of glutamate, or neuronal cell death.[@b6-ndt-10-1763],[@b9-ndt-10-1763],[@b15-ndt-10-1763] The present case did not provide information about the precise mechanisms.

Conclusion
==========

We reported a case of reversible brain atrophy and cognitive impairment in a patient with endogenous Cushing's syndrome. The young age at onset and the short duration of Cushing's syndrome may have contributed to the rapid reversibility of both cognitive dysfunction and brain atrophy in our case. The prevalence of brain atrophy in patients with Cushing's syndrome remains unknown. The presence or absence of causal links between brain atrophy and cognitive impairment in chronic hypercortisolemia is also unclear. However, clinicians may consider Cushing's syndrome as a possible causal condition in patients with cognitive impairment and brain atrophy that is atypical for their age.
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![Transverse T1-weighted magnetic resonance images of the brain.\
**Notes:** (**A**--**C**) Diffuse atrophy of the brain, including the cerebrum, cerebellum, and hippocampus was found, accompanied by dilatation of ventricles, subarachnoid space, and sulci, with an Evans' index of 0.25. (**D**--**F**) Eight months after surgical removal of cortisol-secreting adrenocortical adenoma, brain atrophy recovered. Dilatation of ventricles, subarachnoid space, and sulci was also resolved, with an Evans' index of 0.22.](ndt-10-1763Fig1){#f1-ndt-10-1763}

![Radiological findings.\
**Notes:** (**A**) Plain abdominal computed tomography showed a tumor of 2.7 cm diameter with 35 Hounsfield units (arrow) in the left adrenal gland. (**B**) ^131^I-adosterol scan (posterior view) demonstrated radioisotope accumulation in accordance with the left adrenal mass (arrow), while no uptake was detected on the opposite side.](ndt-10-1763Fig2){#f2-ndt-10-1763}

![Histological findings of the resected left adrenal gland.\
**Notes:** (**A**) Tissue sections stained with hematoxylin and eosin (HE) (20×) demonstrated an apparently marginated encapsulated tumor without any capsular or blood vessel invasion. (**B**) The zona reticularis and fasciculata of the attached non-tumoral adrenal tissue was atrophic (arrow) and showed little expression of dehydroepiandrosterone sulfate (20×). (**C**) The tumor consisted mainly of compact cells and partially of clear cells (HE, 400×). A slight infiltration of lymphocytes (arrow) was observed in the tumor. (**D**) Most of the tumor cells indicated positive immunostaining for 17α-hydoroxylase (400×).](ndt-10-1763Fig3){#f3-ndt-10-1763}

###### 

Laboratory findings in August 2011

  -------------------------------- --------------------------------------------------------------------
  Hematology                       
   White blood cells               10,250/mm^3^
   Red blood cells                 422×10^4^/μL
   Hemoglobin                      13.3 g/dL
   Hematocrit                      38.8%
   Platelets                       18.8×10^4^/mm^3^
  Chemistry                        
   Total protein                   6.3 g/dL
   Albumin                         4.1 g/dL
   Aspartate aminotransferase      27 IU/L
   Alanine aminotransferase        30 IU/L
   Gamma-glutamyl transpeptidase   36 IU/L
   Urea nitrogen                   13 mg/dL
   Creatinine                      0.73 mg/dL
   Sodium                          145 mmol/L
   Potassium                       2.7 mmol/L
   Chloride                        104 mmol/L
   C-reactive protein              0.01 mg/dL
   Fasting plasma glucose          4.9 mmol/L
   Hemoglobin A~1c~                5.2%
  Urine analysis                   
   Specific gravity                1.009
   Glucose                         --
   Protein                         --
   Occult blood reaction           --
   Ketone body                     --
  Endocrinological examination     
   Plasma aldosterone              6.3 ng/dL
   Plasma renin activity           2.0 mg/dL/h
   Serum DHEA-S                    294 ng/mL (240--5,370)[\#](#tfn1-ndt-10-1763){ref-type="table-fn"}
   Plasma cortisol                 
     8 AM                          29.1 μg/dL
     4 PM                          26.2 μg/dL
     12 PM                         26.4 μg/dL
   Plasma ACTH                     
     8 AM                          \<1.0 pg/mL
     4 PM                          \<1.0 pg/mL
     12 PM                         \<1.0 pg/mL
   Urinary free cortisol           1,280 μg/day
  -------------------------------- --------------------------------------------------------------------

**Note:**

Reference range.

**Abbreviations:** ACTH, adrenocorticotropic hormone; DHEA-S, dehydroepiand-rosterone sulfate.
